DDInter1266 DDInter1828
Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its overall tolerability and effectiveness, naproxen can be considered a first line treatment for a variety of clinical situations requiring analgesia. Naproxen is available in both immediate and delayed release formulations, in combination with sumatriptan to treat migraines, and in combination with esomeprazole to lower the risk of developing gastric ulcers.
Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Tolbutamide appears to be metabolized in the liver. Tolbutamide and its metabolites are excreted in urine (75-85%) and feces.
Naproxen {u} (Compound) binds {v} (Gene) SLC22A6
SLC22A6 {u} (Gene) is bound by {v} (Compound) Tolbutamide
Naproxen {u} (Compound) causes {v} (Side Effect) Erythema
Erythema {u} (Side Effect) is caused by {v} (Compound) Tolbutamide
Naproxen {u} (Compound) resembles {v} (Compound) Indomethacin
Indomethacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Naproxen {u} (Compound) binds {v} (Gene) SLC22A6
SLC22A6 {u} (Gene) is bound by {v} (Compound) Probenecid
Probenecid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Naproxen {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Tolbutamide
Naproxen {u} (Compound) causes {v} (Side Effect) Erythema
Erythema {u} (Side Effect) is caused by {v} (Compound) Tolazamide
Tolazamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Naproxen {u} (Compound) resembles {v} (Compound) Indomethacin
Indomethacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Tolbutamide
Naproxen {u} (Compound) resembles {v} (Compound) Suprofen
Suprofen {u} (Compound) resembles {v} (Compound) Bromfenac
Bromfenac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Naproxen {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Clopidogrel
Clopidogrel {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tolbutamide
Naproxen {u} (Compound) causes {v} (Side Effect) Erythema
Erythema {u} (Side Effect) is caused by {v} (Compound) Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Tolbutamide
Naproxen (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Tolbutamide (Compound)
Naproxen (Compound) causes Erythema (Side Effect) and Erythema (Side Effect) is caused by Tolbutamide (Compound)
Naproxen (Compound) resembles Indomethacin (Compound) and Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Naproxen (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Probenecid (Compound) and Probenecid may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Naproxen (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Glipizide (Compound) and Glipizide (Compound) resembles Tolbutamide (Compound)
Naproxen (Compound) causes Erythema (Side Effect) and Erythema (Side Effect) is caused by Tolazamide (Compound) and Tolazamide (Compound) resembles Tolbutamide (Compound)
Naproxen (Compound) resembles Indomethacin (Compound) and Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Naproxen (Compound) resembles Suprofen (Compound) and Suprofen (Compound) resembles Bromfenac (Compound) and Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Naproxen (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Clopidogrel (Compound) and Clopidogrel may cause a minor interaction that can limit clinical effects when taken with Tolbutamide
Naproxen (Compound) causes Erythema (Side Effect) and Erythema (Side Effect) is caused by Glipizide (Compound) and Glipizide (Compound) resembles Tolbutamide (Compound)